Vnitr Lek 2023, 69(5):335-338

Finerenon: další možnost léčby u pacientů s chronickým onemocněním ledvin a diabetem 2. typu

Roman Dvořák, Miroslav Souček
II. interní klinika LF MU a FN u sv. Anny v Brně

Finerenon je selektivní nesteroidní antagonista mineralokortikoidních receptorů. Inhibuje nadměrnou aktivaci těchto receptorů, která u pacientů s chronickým onemocněním ledvin (CKD) a diabetem mellitem 2. typu spouští zánět a fibrózu a vede k progresi renálních a KV onemocnění. Doporučená cílová dávka je 20 mg finerenonu jednou denně podávaná per os. Nejčastějším nežádoucím účinkem finerenonu byl mírný narůst hyperkalemie. Nevykazuje však antiandrogenní nežádoucí účinky. V programu klinických studií finerenon prokázal účinnost při snížení progrese renální insuficience a výskytu KV příhod a příznivý bezpečnostní profil v léčbě pacientů s chronickou renální insuficiencí u diabetiků 2. typu.

Published: September 12, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dvořák R, Souček M. Finerenon: další možnost léčby u pacientů s chronickým onemocněním ledvin a diabetem 2. typu. Vnitr Lek. 2023;69(5):335-338.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vachek J, Tesař V. Finerenon. Vniř Lék. 2023; 69(3): E20-E23. Go to original source... Go to PubMed...
    2. Folkerts K, Millier A, Smela B, et al. Real­‑world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease. J Nephrol. 2022; Nov 23 doi: 10.1007/s40620-022-01492-w. Epub ahead of print. PMID: 36422853. J Nephrol. 2022; Nov 23 doi: 10.1007 Go to original source... Go to PubMed...
    3. Epstein M. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury. From Hans Seley to the Present. Am J Nephrol. 2021; 52: 209-216. Go to original source... Go to PubMed...
    4. Urbánek K. Finerenon: farmakologický profil. Klin Farmakol Farm. 2023; 37(1): 29-32. Go to original source...
    5. Agarwal R, Anker SD, Bakris G, et al. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenon. Nephrol Dial Transplant. 2022; 37(6): 1014-1023. Go to original source... Go to PubMed...
    6. Bakris G, Agarwal R, Chan JC, et al. Effect of Firenenone on Albuminuria in Patients With Diabetic Nephropathy. A Randomised Clinical Trial. JAMA 2015; 314(9): 884-894. Go to original source... Go to PubMed...
    7. Bakris G, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020; 383(23): 2219-2229. Go to original source... Go to PubMed...
    8. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021; 385(24): 2252-2263. Go to original source... Go to PubMed...
    9. Bakris G, Riulope L, Anker SD, et al. FIDELIO­‑DKD and FIGARE­‑DKD Investigators. A prespecified exploratory analysis from FIDELIT examined finerenone use and kidney outcomes in patiets with chronic kidney disease and type 2 diabetes. Kidney Int. 2023 Jan; 130(1): 196-206. Go to original source... Go to PubMed...
    10. A trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non­‑diabetic Chronic Kidney disease (FIND­‑CKD). Available from: https://beta.clinicaltrials.gov/study/NCT05047263.
    11. SPC přípravku Kerendia® Available from: https://www.bayer.com/sites/default/files/Kerendia_SPC.pdf.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.